Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
USD 36.0
(-7.98%)
USD 36.0
(-7.98%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -429.13 Million USD | 24.25% |
| 2022 | -462.79 Million USD | -160.47% |
| 2021 | -217.5 Million USD | -90.07% |
| 2020 | -114.43 Million USD | 76.12% |
| 2019 | -479.12 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -332.79 Million USD | -82.52% |
| 2024 Q1 | -182.29 Million USD | -19.75% |
| 2023 Q2 | -92.18 Million USD | -21.08% |
| 2023 FY | - USD | 23.63% |
| 2023 Q1 | -76.13 Million USD | 64.27% |
| 2023 Q3 | -110.54 Million USD | -19.93% |
| 2023 Q4 | -152.76 Million USD | -38.19% |
| 2022 Q1 | -89.52 Million USD | -78.34% |
| 2022 FY | - USD | -160.47% |
| 2022 Q4 | -213.06 Million USD | -216.78% |
| 2022 Q3 | -67.26 Million USD | 65.8% |
| 2022 Q2 | -196.69 Million USD | -119.71% |
| 2021 Q4 | -50.19 Million USD | 9.17% |
| 2021 Q1 | -235.67 Million USD | 0.0% |
| 2021 Q2 | -171.89 Million USD | 27.06% |
| 2021 Q3 | -55.26 Million USD | 67.85% |
| 2021 FY | - USD | -90.07% |
| 2020 Q2 | -160.58 Million USD | -6.39% |
| 2020 FY | - USD | 76.12% |
| 2020 Q3 | -163.15 Million USD | -1.6% |
| 2020 Q1 | -150.94 Million USD | -11.82% |
| 2019 Q1 | -54.46 Million USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | -134.98 Million USD | -49.23% |
| 2019 Q3 | -90.45 Million USD | 54.59% |
| 2019 Q2 | -199.21 Million USD | -265.76% |
| 2018 Q3 | -54.93 Million USD | -44.13% |
| 2018 Q1 | -83.43 Million USD | -205.24% |
| 2018 Q2 | -38.11 Million USD | 54.32% |
| 2017 Q2 | -25.21 Million USD | -73.95% |
| 2017 Q3 | -39.56 Million USD | -56.9% |
| 2017 Q4 | 79.28 Million USD | 300.37% |
| 2017 Q1 | -14.49 Million USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ADC Therapeutics SA | -146.76 Million USD | -192.405% |
| Alto Neuroscience, Inc. | -34.56 Million USD | -1141.65% |
| Annovis Bio, Inc. | -45.03 Million USD | -852.901% |
| Ginkgo Bioworks Holdings, Inc. | -821.29 Million USD | 47.748% |
| Nuvation Bio Inc. | -99.6 Million USD | -330.862% |
| Nuvation Bio Inc. | -99.6 Million USD | -330.862% |
| Arcus Biosciences, Inc. | -283 Million USD | -51.639% |
| Theriva Biologics, Inc. | -19.85 Million USD | -2061.474% |
| Zymeworks Inc. | -129.95 Million USD | -230.219% |